Pierre Naville was an important figure in the interaction of surrealism and communism. He went on to be a well-known activist on the French left over the course of seven decades.

An injected version of Eisai and Biogen's Alzheimer's drug Leqembi works as well as the current intravenous version at removing toxic brain plaques, according to an analysis presented by Eisai on ...

Even with a full FDA approval, Eisai and Biogen’s latest Alzheimer’s disease med Leqembi appears to be moving slower than expected.

Japan's Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for ...

Eisai Co. said a volunteer died while using the company’s experimental Alzheimer’s drug lecanemab in a clinical trial, but that it wasn’t clear if the death was directly caused by the drug.

Eisai is launching a “digital business” that aims to help predict dementia while also helping those living with the disease live better lives.

Eisai Inc. announced today that screening for Study E2086-A001-101 (Study 101) to assess the efficacy, safety and tolerability of E2086, a novel selective orexin-2 receptor, is now registered on ...

Eisai Inc. held the official grand opening of its new headquarters Aug. 18, the Eisai US hhceco Center in Nutley.

Japanese drugmaker Eisai said Tuesday that Ivan Cheung, chairman of its U.S. operations and global head of its Alzheimer’s disease unit, will retire at the end of the month.

In a widely-anticipated study, Eisai and Biogen on Tuesday said their Alzheimer's drug slowed cognitive decline among people with early signs of the disease. The study, led by Eisai, which has ...

Eisai Alzheimer’s disease drug candidate lecanemab now has data from a pivotal study showing a statistically significant reduction in cognitive decline. Lecanemab is already under FDA review for ...